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9.6% trigeminal neuralgia, 12.8% CRPS, 14.8% post-herpetic
neuralgia, 19.1% entrapment neuropathies, 3.6% post-stroke
pain, 2.7% phantom limb, and 26.5% others. MOS-sleep was
acceptable (items with missing data <10% and ﬂoor and ceiling
effects <50% per item and <15% per domain) and reliable
(Cronbachxs a between 0.64 and 0.87, and test-retest intraclass
correlation coefﬁcients between 0.79 and 0.91, p < 0.001 for all
cases). After adjusting by covariates, MOS-sleep was able to dis-
tinguish between sex, present pain severity, level of disability and
presence of anxiety or depression: sleep-problems index scores
higher in female and patients with horrible/excruciating pain,
anxiety, depression and extreme disability (p < 0.05, all cases).
Concurrent validity with other scales was moderate; Spearman’s
rho coefﬁcients between -0.21 and 0.57 (p < 0.01, all cases).
MOS-sleep was sensitive to change after treatment with
gabapentin; after adjusting, responders (baseline pain reduction
>50%) showed a reduction in sleep-problems index of -25.6 +
14.3pts versus -12.1 + 14.5pts in non responders (F = 80.5, p
< 0.0001). Scoring reduction in summary index and sleep sub-
scales correlated signiﬁcantly with pain improvement (Pearson 
r-coefﬁcients between 0.428 and 0.116, p < 0.01, all cases).
CONCLUSIONS: MOS-sleep showed good psychometric prop-
erties and was sensitive to changes in patients with Neuropathic
pain.
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OBJECTIVES: No epidemiological data are available for hyper-
hidrosis (excessive sweating) in the UK, although a 2.9% preva-
lence rate recently was reported in a census-type study in the
USA. A retrospective cohort study was designed to estimate age-
and sex-speciﬁc incidence and prevalence in patients presenting
to UK general practitioners over 1994–2003. Longitudinal
trends including seasonality were examined and patient man-
agement was analysed in terms of prescription, referral and test
rates. METHODS: The UK General Practice Research Database
(GPRD) includes computerised medical records for 3 million
active patients (~5% of UK population) from over 350 practices.
GPRD coding dictionaries were reviewed to compile a list of
hyperhidrosis-related medical codes (HMC) and prescription
codes (HPC). Many HMCs and HPCs are not used exclusively
for hyperhidrosis, so three cohort deﬁnitions were tested to
explore their speciﬁcity and sensitivity. Prevalence was estimated
by assuming that the condition is chronic with no resolution.
RESULTS: In 2003 the estimated incidence of hyperhidrosis was
0.21% (n = 4267) for patients with an HMC, and 0.08% (n =
1598) for patients with an HMC and an HPC. Incidence doubled
over 1994 to 2003; was 1.5 times higher in females than males;
and was 1.4 times higher in summer (Apr–Sept) than winter
(Oct–Mar). Prevalence was estimated at 1.62% (32,406) in
2003. There were 2831 referrals associated with HMCs over
1994–2003, of which 986 were to pathology, 541 to general
medical and only 425 to dermatology. Prescriptions for anti-
perspirants were written for 6324 patients, but only 713 received
more than 5 prescriptions in total over 1994–2003. CONCLU-
SIONS: The GPRD is a useful tool to investigate the epidemiol-
ogy and treatment of hyperhidrosis in the UK. Potential
misclassiﬁcation of cases was explored using different cohort def-
initions. Referral rates by general practitioners were low and rel-
atively few patients persisted with anti-perspirants.
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OBJECTIVES: The aim of this study was to assess the cost-effec-
tiveness of imiquimod cream 5%, in the treatment of superﬁcial
basal cell carcinomas (sBCC) compared to usual care in Norway.
METHODS: The cost-effectiveness analysis was performed
using a decision model, comparing imiquimod, a topical immune
response modiﬁer, with usual care in a Norwegian practice
setting. Estimates of initial clearance and recurrence in sBCC are
from randomized clinical trials of imiquimod and from literature
reviews supplemented by assessments from structured interviews
with clinical dermatologists. RESULTS: Dermatologists reported
the distribution of treatment options for sBCC in Norway as
surgery (30%), cryosurgery (40%) and photodynamic therapy
(30%). A weighted composite outcome of these three alterna-
tives (usual care) was used as basis for the comparison. Adverse
events and their consequences in terms of treatment costs were
considered in the model. The model estimates of initial clearance
with imiquimod compared to usual care in sBCC was 94% vs.
88%. The analysis found imiquimod to be slightly more expen-
sive per patient (NOK133 per year). The incremental cost-effec-
tiveness ratio (ICER) for imiquimod compared to usual care was
NOK1973 per recurrence avoided based on a 1-year time per-
spective. For individual therapy options, imiquimod dominated
PDT, was more expensive but with better outcomes than
cryosurgery, yet was dominated by excision surgery. CONCLU-
SION: The total cost of treatment with imiquimod was margin-
ally higher than the weighted average for usual care, but the
treatment with imiquimod substantially reduced recurrence of
sBCC. Similar to most other measures of effect, there are no
general accepted levels for the societies’ willingness to pay for
avoided recurrences of sBCC; even so, based on this analysis it
is reasonable to conclude that imiquimod provides a cost-
effective treatment option for sBCC in Norway.
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OBJECTIVE: To assess the costs, consequences and cost-effec-
tiveness of Elidel (pimecrolimus cream 1%) in treatment of chil-
dren with atopic dermatitis in Hungary. METHODS: A Markov
model for atopic dermatitis developed by the Erasmus Univer-
sity (Rotterdam, The Netherlands) was adapted to the Hungar-
ian health care settings. The model based on a double-blind,
multicenter, randomized, parallel-group study. Patients were 
randomised (2:1) to receive pimecrolimus treatment paradigm
(i.e. emollients, pimecrolimus, medium potency topical corticos-
teroids) or standard of care (emollients, vehicle, medium potency
topical corticosteroids). The study was conducted in children and
adolescents (2 to 18 years of age). Hungarian cost vectors were
calculated by linking severity of disease as deﬁned by Investiga-
tor’s Global Assessment (IGA) to average resource use. Resource
use was multiplied by drug costs and unit costs as published in
ofﬁcial databases. RESULTS: Pimecrolimus treatment has an
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incremental cost of HUF 143,897 over standard care. This addi-
tional cost of care resulted in an incremental 0.05 QALY gain
over the 6 months period. The incremental cost effectiveness
ratio was 2,863,913 HUF/QALY for the pimecrolimus therapy.
CONCLUSIONS: Pimecrolimus is more cost-effective than
many other health care interventions currently reimbursed by the
Hungarian National Health Fund.
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OBJECTIVES: To evaluate short-term and long-term cost-
effectiveness of imiquimod versus surgery in the treatment of
superﬁcial basal cell carcinoma in The Netherlands. METHODS:
A decision analytic model adopting a societal perspective was
developed and compared cost and outcomes of imiquimod vs.
surgery. The short-term (18 weeks) effectiveness outcome was
histological clearance, with sustained clearance the outcome at
3 years. Direct costs included costs of excision and Moh’s
surgery, drugs, adverse events, follow-up and transportation.
Indirect costs comprise working hours lost due to dermatologist
and surgery visits. Data were derived from clinical trials
(Imiquimod histological clearance and recurrence rates), Delphi
panel (resource utilisation) and published literature (surgery
response and recurrence rates). Cost data were taken from ofﬁ-
cial costing guide and tariff lists. Two scenarios were used for
calculating surgery costs: 1) micro-costing (using average time
and supplies obtained from the Delphi panel), and 2) a Dutch
study on the costs of surgery. Long-term costs were discounted
at 4%. RESULTS: Compared with surgery, short-term savings
with imiquimod were €79 and €97 per patient for scenarios 1
and 2 respectively [total costs: €585 vs. €663 and €590 vs. €687].
Histological clearance of 82% for imiquimod and 91% for
surgery made imiquimod a cost-effective treatment option. Long-
term costs with imiquimod were an extra €148 and €133 for 
scenarios 1 and 2 [total costs: €1471 vs. €1322 and €1479 vs.
€1346], while sustained clearance with imiquimod was 87% vs.
96% for surgery. The model showed moderate sensitivity to
changes in response and recurrence rates, response to treatment,
and numbers of working days lost. CONCLUSION: While
imiquimod is cost-effective in the short-term, long-term cost-
effectiveness should be judged with prudence because of the
uncertainty surrounding long-term recurrence data. Non-tangi-
ble beneﬁts, such as patient preference for avoiding surgery and
patient convenience were not quantiﬁed in the model either.
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OBJECTIVES: To examine the cost-effectiveness (CE) of brivu-
dine over aciclovir in the treatment of herpes zoster in Germany.
METHODS: This CE analysis used effectiveness data from a
double-blind RCT comparing brivudine (125mg p.o. once daily)
with aciclovir (800mg p.o. ﬁve times daily). Treatment with
brivudine showed a 25% reduction in postherpetic neuralgia
(PHN). Based on the IMS prescription index, the 2004 incidence
of herpes zoster in Germany was 348,000 cases, with 15.74%
consecutive cases of PHN under brivudine and 21% PHN cases
under aciclovir. Cost data were obtained from public price lists.
One therapy cycle with brivudine or aciclovir costs €95.67 and
€32.83 respectively; analgesics for PHN cost an average €1500
annually. The study was conducted considering direct costs only.
A sensitivity analysis accounted for varying costs for treating
PHN and age-dependent PHN incidences. RESULTS: A total of
54,775 PHN cases under brivudine and 73,080 cases under aci-
clovir were calculated, producing total annual treatment costs of
€115,455,660 and €121,044,840. Treatment with brivudine
saved costs of €305.34 per PHN case avoided. The sensitivity
analysis considered that 60% of herpes zoster patients are 60
years or older (IMS Disease Analyzer 2002), resulting in differ-
ent numbers of PHN cases depending on age and antiviral
therapy. ICERs of brivudine ranged for the older age group
between €694.66 (PHN therapy cost: €500) and -€1805.34
(PHN therapy cost: €3000). Corresponding values for the
younger age group were €1827.66 and -€672.34. Both antiviral
therapies produced equal annual total therapy costs if PHN
therapy amounted to €1200. CONCLUSIONS: Although three
times more expensive, brivudine proved cost effective over aci-
clovir, producing savings if PHN therapy costs were equal to or
higher than €1200. Since effective analgesic therapy would cost
an average €3000 annually, brivudine may be recommended as
ﬁrst-choice treatment because of its cost-saving potential and
convenient once-daily dosage.
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